News Release Details

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a privately held ophthalmic company developing and commercializing targeted therapeutics for the treatment of sight-threatening diseases, today announced the appointment of Gerald D. Cagle, Ph.D., to the company’s Board of Directors. Dr. Cagle is the former Senior Vice President and Chief Scientific Officer of Alcon Laboratories, Inc.

“We are delighted to have Dr. Cagle join our Board of Directors”

“We are delighted to have Dr. Cagle join our Board of Directors,” said Daniel White, Clearside’s President and CEO. “Dr. Cagle’s significant experience in pharmaceutical and clinical ophthalmological product development experience as well as his relationship within the industry will be invaluable to Clearside as we enter into the clinic with our own portfolio.”

“Clearside is poised to make a great contribution to the treatment of ophthalmic diseases with its microinjection platform,” said Dr. Cagle. “This proprietary process and the company’s experienced management team are great assets, and I look forward to playing a role in Clearside’s growth and success.”

At Alcon, Dr. Cagle served as Senior Vice President, Research & Development from 1997 to 2008. He assumed the additional position of Chief Scientific Officer in 2006.

Dr. Cagle began his 32-year career at Alcon in 1976 as a senior scientist in Microbiology. He quickly advanced to lead the Product Development organization and was named vice president, Product Development, in 1985. He also served a two-year assignment as the vice president of Regulatory Affairs. Under Dr. Cagle's leadership, Alcon's Research & Development group grew to 1,300 employees in 18 countries.

Dr. Cagle received his B.S. degree from Wayland College in Plainview, Texas. He earned both a M.S. and a Ph.D. from the University of North Texas in Denton, Texas. He is currently Senior Advisor and Head of Business Development for GrayBug, LLC (Baltimore, Md.) and serves as Chief Operating Officer for Cognoptix (Acton, Mass.).

Christy Shaffer of Hatteras Venture Partners and Clearside’s Board Chair, said, “Jerry is a perfect complement to Clearside’s Board of Directors and Clearside’s dynamic culture as the company continues down a path of rapid growth and the development of scientific understanding of treating retinal disease with the proprietary delivery of pharmaceuticals through the suprachoroidal space.”

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, Ga., is a clinical-stage ophthalmic pharmaceutical company that develops and commercializes targeted therapeutics to treat sight-threatening diseases. Clearside treats the pathological changes to the blood retinal barrier that lead to retinal blindness by delivering therapeutics through the suprachoroidal space to the retina and choroid using a proprietary microinjection dosage form. Clearside Biomedical was founded by an executive team with extensive development and revenue growth expertise. This team strives for better delivery and performance of its therapeutic agents to improve the standard of care for patients with retinal and choroidal disease. Visit www.clearsidebiomedical.com for more information.